ClinicalTrials.gg

Friedreich Ataxia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 111 studies for Friedreich Ataxia across more than 10 countries. 28 are recruiting or about to start. 102 of them are mainly about Friedreich Ataxia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
66
Recruiting
18
Active, not recruiting
9
Not yet recruiting
7
Enrolling by invitation
3
Withdrawn
3

Phase

Phase 2
36
Phase 1
23
Phase 3
16
Early Phase 1
2
Phase 4
2

Where

United States
71
France
23
Italy
22
Germany
18
Spain
13
Australia
13

Who develops what

Add Friedreich Ataxia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 8 programs from 8 companies, 8 with this as their studies’ main aim; 3 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Biogen, Neurocrine Biosciences and PTC Therapeutics here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
omaveloxoloneApproved: US 2023 · EU 2024☆ Track1 live phase-3 study: NCT06953583Biogen
alpha-tocotrienol quinone☆ Track2 live phase-3 studies: NCT07681713, NCT05515536PTC Therapeutics
nomlabofusp☆ Track1 live phase-3 study: NCT07778836Larimar Therapeutics, Inc.

The 3 in phase 3 with the nearest primary completion, of 8 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.DT-216P2 · Design Therapeutics, Inc. · Phase 2 main aimNCT06874010 A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia — primary endpoint: Frequency of treatment-emergent adverse events (TEAE) · 20 enrolled
  • Jan 2027 est.nomlabofusp · Larimar Therapeutics, Inc. · Phase 2 main aimNCT06447025 An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia — primary endpoint: Number of subjects with treatment-emergent adverse events (TEAEs) by System Organ Class (SOC), Preferred Term (PT) and Maximum Severity · 85 enrolled
  • Jul 2027 est.GV101 · Graviton Bioscience Corporation · Phase 2 main aimNCT07870590 GV101 for Friedreich's Ataxia (FA) Treatment — primary endpoint: Mean percent change in frataxin-M protein · 48 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Friedreich Ataxia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

12studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 18 Friedreich Ataxia studies recruiting now, 9 (50%) set no upper age limit and 9 (50%) stop at 75 or younger. 15 (83%) take children under 18. 1 (6%) are for women only and 0 (0%) for men only; 3 (17%) take healthy volunteers.

Recruiting studies that take each age, of 18
AgeWomenMen
108 (44%)8 (44%)
1818 (100%)17 (94%)
3018 (100%)17 (94%)
4018 (100%)17 (94%)
5016 (89%)15 (83%)
6512 (67%)11 (61%)
759 (50%)8 (44%)
859 (50%)8 (44%)

Across all 111 studies, recruiting or not: 60% stop at 75 or younger and 56% at 65; 64% take children; 2% are for women only and 1% for men only; 15% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Friedreich Ataxia studies take

Of 12 phase 2 interventional studies under Friedreich Ataxia, half reached primary completion within 22 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 222 mo14–34 · 12 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 111. Browse all 111 → or search them.